Her2 s310f specific antigen-binding molecules
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsTatsushi KODAMA, Yang SUN
Life of this patent
Estimating the term…
Abstract
An objective of the present invention is to provide antigen-binding molecules that specifically bind to HER2 mutant. The present invention provides antigen-binding molecules that specifically bind to HER2 mutant, and are capable of modulating and/or activating an immune response; compositions comprising the antigen-binding molecule; and methods of using the same.
Claims7
-15. (canceled)
A method of treating cancer, comprising administering to an individual having a cancer expressing human HER2 with a S310F mutation (HER2 S310F) an effective amount of a polypeptide comprising a single means for binding human HER2 S310F and a CD3 antigen binding domain, wherein the means for binding human HER2 S310F does not bind to wild type human HER2.
Dependencies are inferred from the claim text.